View Post

Polio is an Imminent Threat to New York's Public Health

In COVID-19, Latest News by Precision Vaccinations

New York Governor Kathy Hochul recently announced additional steps New York State is taking to address evidence of circulating poliovirus in New York State, including an official declaration to further support local health departments in driving immunizations.
On September 28, 2022, New York State Health Commissioner Dr. Mary T. Bassett declared poliovirus an imminent threat to public health in New York State.

View Post

Monkeypox Intradermal Vaccination Offers Several Benefits

In COVID-19, Latest News by Precision Vaccinations

Despite limited clinical evidence, all available data suggest that intradermal administration of the Bavarian Nordic-produced Jynneos® vaccine will be as immunogenic as subcutaneous dosing for preventing monkeypox infection and illness, which leads us to favor intradermal use from both the individual and public health perspectives, wrote a group of vaccine experts.
'Vaccines work only if they are accessible, trusted, and used.'

View Post

Menstrual Cycle Disrupted by COVID-19 Vaccination

In COVID-19, Latest News by Precision Vaccinations

Early in 2022, a study funded by the U.S. National Institutes of Health (NIH) found women receiving one dose of a COVID-19 vaccine during a single menstrual cycle had an increase in cycle length of nearly one day.
Recently, a large international study funded by the NIH confirmed those findings linking COVID-19 vaccination with an average increase in menstrual cycle length of less than one day.
For most study participants, the increase resolved in the cycle following vaccination.

View Post

Real-World Data Show Cell-Based and Adjuvanted Flu Shots Can Reduce Influenza Burden

In COVID-19, Latest News by Precision Vaccinations

New data announced today from four real-world studies shows the impact that cell-based and adjuvanted influenza vaccines can have in reducing the burden of seasonal influenza on hospitals and health systems.
The data from CSL Seqirus were presented at OPTIONS for the Control of Influenza (OPTIONS XI), being held in the United Kingdom.